secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001641172-25-010112
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata: XYNGARI Phase 3 STAR-1 acne trial meets co-primary endpoints; cash $9.7M
--------------------------------------------------------------------------------

- XYNGARI Phase 3 STAR-1 achieved statistically significant results on all co-primary endpoints at all time points vs placebo.
- Entered clinical trial collaboration with Revance to study DMT410 with DAXXIFY for axillary hyperhidrosis.
- Raised $8.8M gross proceeds from private placement and warrant inducement financings in Q1 2025.
- Cash and equivalents $9.7M as of March 31, 2025, up from $3.2M; expected to fund operations into Q1 2026.
- R&D expenses $1.3M, G&A $1.1M; operating cash burn $1.9M in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225010112/0001641172-25-010112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225010112/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer